Literature DB >> 28818268

"Metformin-resistant" folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea.

Abdullah Olgun1.   

Abstract

Metformin, first line medication in the treatment of type2 diabetes by millions of patients worldwide, causes gastrointestinal adverse effects (i.e. diarrhea) in approximately 30% of patients, frequently leading to discontinuation. Interestingly, metformin was reported to increase life span in a microscopic worm, Caenorhabditis elegans, by decreasing folate and methionine production of bacteria that this worm uses as a food source. Metformin can be expected to have a similar effect on some microorganisms of human gut microbiota. This can disturb the balance of gut microbiota and cause gastrointestinal adverse effects by altering folate production of some types of bacteria and suppress their growth. Metformin resistant probiotics can be discovered or generated by artificial evolution/selection, and used to prevent these adverse effects. These patients can also be managed with folate supplementation.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28818268     DOI: 10.1016/j.mehy.2017.07.009

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

1.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin.

Authors:  Lulu Sun; Cen Xie; Guang Wang; Yue Wu; Qing Wu; Xuemei Wang; Jia Liu; Yangyang Deng; Jialin Xia; Bo Chen; Songyang Zhang; Chuyu Yun; Guan Lian; Xiujuan Zhang; Heng Zhang; William H Bisson; Jingmin Shi; Xiaoxia Gao; Pupu Ge; Cuihua Liu; Kristopher W Krausz; Robert G Nichols; Jingwei Cai; Bipin Rimal; Andrew D Patterson; Xian Wang; Frank J Gonzalez; Changtao Jiang
Journal:  Nat Med       Date:  2018-11-05       Impact factor: 53.440

Review 2.  Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.

Authors:  Tsvetalina Tankova; Elżbieta Senkus; Maria Beloyartseva; Simona Borštnar; Doina Catrinoiu; Mona Frolova; Alinta Hegmane; Andrej Janež; Mladen Krnić; Zoltan Lengyel; Yiola Marcou; Laura Mazilu; Bela Mrinakova; Ruth Percik; Katarina Petrakova; Gábor Rubovszky; Margarita Tokar; Eduard Vrdoljak
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

3.  A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.

Authors:  Shih-Chen Fu; Chung-Han Lee; Yi-Chen Hsieh; Pei-Hua Wu; Sheng-Hsuan Lin; Hsiuying Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-04-05       Impact factor: 6.073

Review 4.  Crisis of the Asian gut: associations among diet, microbiota, and metabolic diseases.

Authors:  Phatthanaphong Therdtatha; Akari Shinoda; Jiro Nakayama
Journal:  Biosci Microbiota Food Health       Date:  2022-02-09

5.  Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients.

Authors:  Ilze Elbere; Ivars Silamikelis; Ilze Izabella Dindune; Ineta Kalnina; Monta Ustinova; Linda Zaharenko; Laila Silamikele; Vita Rovite; Dita Gudra; Ilze Konrade; Jelizaveta Sokolovska; Valdis Pirags; Janis Klovins
Journal:  PLoS One       Date:  2020-10-30       Impact factor: 3.240

Review 6.  An Update on the Effectiveness of Probiotics in the Prevention and Treatment of Cancer.

Authors:  Vidya Sankarapandian; Balu Alagar Venmathi Maran; Ramya Lakshmi Rajendran; Manasi P Jogalekar; Sridharan Gurunagarajan; Rajapandiyan Krishnamoorthy; Prakash Gangadaran; Byeong-Cheol Ahn
Journal:  Life (Basel)       Date:  2022-01-02

7.  Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial.

Authors:  Noel T Mueller; Moira K Differding; Mingyu Zhang; Nisa M Maruthur; Stephen P Juraschek; Edgar R Miller; Lawrence J Appel; Hsin-Chieh Yeh
Journal:  Diabetes Care       Date:  2021-05-18       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.